Hypothesized to be the result of the selective pressure of BCL2i therapy throughout the hematopoietic compartment, this is primarily manifest as loss of function BAX variants which may be detected in remission in patients with CLL on BCL2i with single-cell sequencing showing presence within the myeloid and NK-cell compartments [81]. The gene discussed is BAX; the disease is B-cell chronic lymphocytic leukemia.